Cancer Care Ontario | Action Cancer Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

821 Results

Document

OBSP-Patient-Information-Sheet

Nov 2023

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Document

obsp-11-23-23.xml

Nov 2023

Document

obsp-11-23-23.html

Nov 2023

Document

obsp-12-04-23.xml

Dec 1969

Document

obsp-12-04-23.html

Dec 1969

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Document

obsp-12-13-23.xml

Dec 1969

Document

obsp-12-12-23.xml

Dec 1969

Document

obsp-12-12-23a.xml

Dec 1969

Document

obsp-12-13-23.html

Dec 1969

Document

obsp-12-13-23a.xml

Dec 1969

Pages